These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 38978480)

  • 1. Chemical approaches to probe and engineer AAV vectors.
    Pham Q; Glicksman J; Chatterjee A
    Nanoscale; 2024 Jul; 16(29):13820-13833. PubMed ID: 38978480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical Modifications of the Capsid for Redirecting and Improving the Efficacy of Adeno-Associated Virus Vectors.
    Lam AK; Frabutt D; Li L; Xiao W
    Hum Gene Ther; 2021 Dec; 32(23-24):1433-1438. PubMed ID: 34254844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Genome Packaging Efficiency of Adeno-associated Virus Vectors Using Rep Hybrids.
    Mietzsch M; Eddington C; Jose A; Hsi J; Chipman P; Henley T; Choudhry M; McKenna R; Agbandje-McKenna M
    J Virol; 2021 Sep; 95(19):e0077321. PubMed ID: 34287038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probe capsid structure stability and dynamics of adeno-associated virus as an important viral vector for gene therapy by hydrogen-deuterium exchange-mass spectrometry.
    Ye X; Hu Y; Qiu H; Li N
    Protein Sci; 2024 Jul; 33(7):e5074. PubMed ID: 38888268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of AAV Serotypes 4, 5, and 11.
    Earley LF; Powers JM; Adachi K; Baumgart JT; Meyer NL; Xie Q; Chapman MS; Nakai H
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27852862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy.
    Nance ME; Duan D
    Hum Gene Ther; 2015 Dec; 26(12):786-800. PubMed ID: 26414293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of Assembly-Activating Protein for Adeno-associated Virus Vector Production and Capsid Protein Stability in Mammalian and Insect Cells.
    Grosse S; Penaud-Budloo M; Herrmann AK; Börner K; Fakhiri J; Laketa V; Krämer C; Wiedtke E; Gunkel M; Ménard L; Ayuso E; Grimm D
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach.
    Havlik LP; Simon KE; Smith JK; Klinc KA; Tse LV; Oh DK; Fanous MM; Meganck RM; Mietzsch M; Kleinschmidt J; Agbandje-McKenna M; Asokan A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precise Manipulation of the Site and Stoichiometry of Capsid Modification Enables Optimization of Functional Adeno-Associated Virus Conjugates.
    Erickson SB; Pham Q; Cao X; Glicksman J; Kelemen RE; Shahraeini SS; Bodkin S; Kiyam Z; Chatterjee A
    Bioconjug Chem; 2024 Jan; 35(1):64-71. PubMed ID: 38103182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative structural, biophysical, and receptor binding study of true type and wild type AAV2.
    Bennett A; Hull J; Jolinon N; Tordo J; Moss K; Binns E; Mietzsch M; Hagemann C; Linden RM; Serio A; Chipman P; Sousa D; Broecker F; Seeberger P; Henckaerts E; McKenna R; Agbandje-McKenna M
    J Struct Biol; 2021 Dec; 213(4):107795. PubMed ID: 34509611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Machine-learning-guided Directed Evolution for AAV Capsid Engineering.
    Fu X; Suo H; Zhang J; Chen D
    Curr Pharm Des; 2024; 30(11):811-824. PubMed ID: 38445704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants.
    Rapti K; Maiakovska O; Becker J; Szumska J; Zayas M; Bubeck F; Liu J; Gerstmann E; Krämer C; Wiedtke E; Grimm D
    J Vis Exp; 2022 Oct; (188):. PubMed ID: 36342179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation AAV vectors for clinical use: an ever-accelerating race.
    Weinmann J; Grimm D
    Virus Genes; 2017 Oct; 53(5):707-713. PubMed ID: 28762205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Context-Specific Function of the Engineered Peptide Domain of PHP.B.
    Martino RA; Fluck EC; Murphy J; Wang Q; Hoff H; Pumroy RA; Lee CY; Sims JJ; Roy S; Moiseenkova-Bell VY; Wilson JM
    J Virol; 2021 Sep; 95(20):e0116421. PubMed ID: 34346767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering AAV receptor footprints for gene therapy.
    Madigan VJ; Asokan A
    Curr Opin Virol; 2016 Jun; 18():89-96. PubMed ID: 27262111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site.
    Huang LY; Patel A; Ng R; Miller EB; Halder S; McKenna R; Asokan A; Agbandje-McKenna M
    J Virol; 2016 Jun; 90(11):5219-5230. PubMed ID: 26962225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Engineering of AAV Capsid Gene for Gene Therapy Application.
    Liu Y; Zhang X; Yang L
    Curr Gene Ther; 2020; 20(5):321-332. PubMed ID: 32998676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SUMOylation Targets Adeno-associated Virus Capsids but Mainly Restricts Transduction by Cellular Mechanisms.
    Chen Q; Njenga R; Leuchs B; Chiocca S; Kleinschmidt J; Müller M
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids.
    Chamberlain K; Riyad JM; Weber T
    Hum Gene Ther Methods; 2016 Feb; 27(1):1-12. PubMed ID: 26757051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy.
    Rodríguez-Márquez E; Meumann N; Büning H
    Expert Opin Biol Ther; 2021 Jun; 21(6):749-766. PubMed ID: 33331201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.